<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104356">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109861</url>
  </required_header>
  <id_info>
    <org_study_id>KFE2011.06</org_study_id>
    <secondary_id>2011-003791-37</secondary_id>
    <nct_id>NCT02109861</nct_id>
  </id_info>
  <brief_title>Microdose Study of Melphalan, Bortezomib and Dexamethasone</brief_title>
  <acronym>Phase-0-MM</acronym>
  <official_title>Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gregersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg Universityhospital</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify specific genes that are up- or downregulated in
      multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib
      (Velcade®) or Dexamethasone (Dexaven®). The study treatment constitutes 1% of the planned
      standard myeloma treatment and will be given two hours prior to standard treatment. Blood
      samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in gene expression at 15, 30, 60, 120 minutes upon microdose drug exposure.</measure>
    <time_frame>Prior to microdose and 15, 30, 60 and 120 minutes post-microdose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is determination of differential and significantly expressed genes across time successive samples from each individual patient. The analysis will be based on global gene expression profiling and differentially expressed genes will be identified using pairwise comparisons of samples means by two sample t-tests and corrections for multiple testing.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan</description>
    <arm_group_label>Melphalan</arm_group_label>
    <other_name>Alkeran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Dexaven®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned treatment for Multiple Myeloma (newly diagnosed as well as relapse and
             refractory disease) with one of the following chemotherapy regimens: 1) Highdose
             melphalan, 2) Bortezomib or 3) Dexamethasone

          -  18 years or older.

          -  Understand and have the will to sign the informed consent.

        Exclusion Criteria:

          -  Prior treatment with the study drug

          -  Received treatment with biphosphonates in the week prior to study treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Gregersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital, Department of Haematology, 9000 Aalborg, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Gregersen, MD, PhD</last_name>
    <phone>+45 99 32 63 26</phone>
    <email>henrik.gregersen@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asta Svirskaite, MD</last_name>
    <phone>+45 99 32 63 59</phone>
    <email>assv@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Haematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Gregersen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asta Svirskaite, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Universityhospital</investigator_affiliation>
    <investigator_full_name>Henrik Gregersen</investigator_full_name>
    <investigator_title>Consultant haematologist, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Phase 0 study</keyword>
  <keyword>Microdose study</keyword>
  <keyword>Micro array</keyword>
  <keyword>Gene expression profiling</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
